Amarin's Other Investors

Amarin raised a round of funding on , . Investors include Thomas McNerney & Partners.

Amarin is a late-stage biopharmaceutical company with a focus on cardiovascular disease. The Companys lead product candidate is AMR101, a prescription grade Omega-3 fatty acid comprising not less than…

Articles about Amarin's Other Investors: